Artivion(NYSE) AORT

Artivion, Inc. makes tools that help doctors fix heart problems. These products treat patients with serious artery diseases. Surgeons use these to replace valves and seal wounds.

Heart and Vascular Solutions

• Aortic Stent Grafts: Mesh tubes used to repair the aorta during surgery; accounted for 37% of revenue for the three months ended June 30, 2026.
• On-X Heart Valves: Mechanical valves used to replace damaged heart or aortic valves; represented 24% of revenue for the three months ended June 30, 2026.
• Preservation Services: Processing of human heart and vascular tissues for transplant; accounted for 21% of revenue for the three months ended June 30, 2026.
• Surgical Sealants: Medical glue used to stop bleeding in large blood vessels; represented 15% of revenue for the three months ended June 30, 2026.

New Tools and Acquisitions

• Acquired Endospan in May 2026 to add the NEXUS family of stent grafts to the product line.
• Received full commercial approval from the Food and Drug Administration in June 2026 for the AMDS Hybrid Prosthesis.
• Began manufacturing PerClot hemostatic powder in the second quarter of 2023 under a supply agreement with Baxter International.
• Expanded international reach through a direct sales force in Europe and various distributors in global markets.

Why Artivion Is Unique

The company maintains a rare combination of manufacturing advanced synthetic medical devices and processing biological human tissues for surgical use. This dual expertise allows it to serve cardiac and vascular surgeons across the entire treatment process for complex aortic disease.

Recent Financial Data

• Revenue was $125.8 million for the three months ended June 30, 2026, up 11% year over year.
• Gross margin was 64% in the three months ended June 30, 2026, compared to 65% in the same period in 2025.
• Total principal debt stood at $370.0 million as of June 30, 2026.
• Research and development spending was $9.1 million for the three months ended June 30, 2026, up 28% year over year.
• Constant currency revenue, which removes the effect of exchange rate changes, rose 9% in the second quarter of 2026.

Evolution of Artivion

Artivion has evolved from a general tissue processing company into a specialized developer of aortic medical technologies. Its recent acquisitions and regulatory approvals reflect a strategic focus on the complex cardiac and vascular surgery markets.